Cryoglobulinemic vasculitis (cryo-vasculitis) is a form of small vessel vasculitis caused by the precipitation of abnormal proteins in the blood, known as cryoglobulins. These proteins clump together at lower temperatures and cause inflammation in the vessel wall. The disease can manifest itself in skin abnormalities (such as purple spots or ulcers), joint problems, nerve pain, and sometimes kidney involvement. Cryo-vasculitis is often secondary to other diseases, such as hepatitis C, autoimmune diseases, or certain blood disorders. According to the CHCC 2012 classification, it belongs to the primary systemic vasculitides of small vessels.
Vasculitis International is pleased to extend its warmest congratulations to the Vasculitis Foundation (VF) on the occasion of its 40th anniversary. On behalf of the
Vasculitis International has published its position statement on the ongoing regulatory review of TAVNEOS® (avacopan) — and warns that data integrity and risk/benefit analysis are two very different issues and must not be treated as one, when taking action. Otherwise the patient pays for science failure.
The FDA has moved from a review to a formal proposal to withdraw approval of Tavneos in the United States.
This is a more serious step than a review, but it is still not a final decision.
In Europe, the EMA review is still ongoing. No conclusions have been reached yet, and Tavneos is still available.